1) Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003;348(8):694-701.
2) Womer RB, West DC, Krailo MD, et al. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma:a report from the Children's Oncology Group. J Clin Oncol 2012;30(33):4148-54.
3) Mascarenhas L, Felgenhauer JL, Bond MC, et al. Pilot study of adding Vincristine, Topotecan, and Cyclophosphamide to interval-compressed chemotherapy in newly diagnosed patients with localized Ewing sarcoma:A report from the Children's Oncology Group. Pediatr Blood Cancer 2016;63(3):493-8.
4) Ladenstein R, Potschger U, Deley MC, et al. Primary disseminated multifocal Ewing sarcoma:Results of the Euro-EWING 99 Trial. J Clin Oncol 2010;28(20):3284-91.
5) Crist WM, Anderson JR, Meza JL, et al. Intergroup Rhabdomyosarcoma Study-IV:Results for patients with nonmetastatic disease. J Clin Oncol 2001;19(12):3091-102.
6) Arndt CAS, Stoner JA, Hawkins DS, et al. Vincristine, Actinomycin, and Cyclophosphamide compared with Vincristine, Actinomycin, and Cyclophosphamide alternating with Vincristine, Topotecan, and Cyclophosphamide for intermediate-risk Rhabdomyosarcoma:Children's Oncology Group Study D9803. J Clin Oncol 2009;27(31):5182-8.